Literature DB >> 8606082

Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide.

L C Paoletti1, R A Ross, K D Johnson.   

Abstract

The capsular polysaccharide (CPS) of group B streptococci (GBS) is an important virulence factor that also serves to protect cells from nonspecific host defense mechanisms. Expression of CPS by GBS, as with other encapsulated bacterial pathogens, is not constitutive but varies during growth in vitro and in primary cultures isolated from different sites of infection. Despite this understanding, little is known about regulation of this surface-expressed carbohydrate antigen in GBS. Here we report that expression of type III CPS by GBS strain M781 grown in continuous culture with a modified chemically defined medium is regulated by growth rate. Cells in steady state at mass doubling times (tds) of 0.8, 1.4, and 1.6 h expressed an average of sixfold more cell-associated CPS than did cells held at tds of 2.3 and 11 h. Strain M781 grown at a td of 1.4 h repeatedly produced more type III CPS than those held at a td of 11.0 h, even when limited for glucose, pyridoxamine, or thiamine. In our studies, > or = 93% of the total CPS expressed by strain M781 was cell associated. Strain M781 grown at a td of 11.0 h (i.e., lowered CPS expression) was susceptible to in vitro complement-mediated opsonophagocytosis and killing by human peripheral blood leukocytes, whereas cells grown at a td of 1.4 h (i.e., higher CPS expression) were not killed unless type III CPS-specific antibody was present. Factors that allow GBS to asymptomatically colonize women yet cause invasive infection to both mother and infant are poorly understood. Our results shed new light on parameters that regulate the pathogenic potential of GBS and may also serve as a way to discern more fully the genetics and biochemistry of GBS capsule synthesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8606082      PMCID: PMC173907          DOI: 10.1128/iai.64.4.1220-1226.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Adherence of Streptococcus agalactiae to synchronously growing human cell monolayers without lipoteichoic acid involvement.

Authors:  S Miyazaki; O Leon; C Panos
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

2.  Properties of high and low density subpopulations of group B streptococci: enhanced virulence of the low density variant.

Authors:  S Håkansson; A M Bergholm; S E Holm; B Wagner; M Wagner
Journal:  Microb Pathog       Date:  1988-11       Impact factor: 3.738

3.  Capsular polysaccharide regulates neutrophil complement receptor interactions with type III group B streptococci.

Authors:  M S Edwards; M R Wessels; C J Baker
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

4.  Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus.

Authors:  H J Jennings; K G Rosell; E Katzenellenbogen; D L Kasper
Journal:  J Biol Chem       Date:  1983-02-10       Impact factor: 5.157

5.  Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus.

Authors:  H J Jennings; E Katzenellenbogen; C Lugowski; D L Kasper
Journal:  Biochemistry       Date:  1983-03-01       Impact factor: 3.162

6.  Lysis and protoplast formation of group B streptococci by mutanolysin.

Authors:  G B Calandra; R M Cole
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

7.  Quantitative relationship between capsular content and killing of K1-encapsulated Escherichia coli.

Authors:  C Vermeulen; A Cross; W R Byrne; W Zollinger
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

8.  Loss of capsule expression by Haemophilus influenzae type b results in enhanced adherence to and invasion of human cells.

Authors:  J W St Geme; S Falkow
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

9.  Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease.

Authors:  J M Musser; S J Mattingly; R Quentin; A Goudeau; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

10.  Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide.

Authors:  H J Jennings; C Lugowski; D L Kasper
Journal:  Biochemistry       Date:  1981-08-04       Impact factor: 3.162

View more
  22 in total

1.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Differential expression of Vibrio vulnificus capsular polysaccharide.

Authors:  A C Wright; J L Powell; M K Tanner; L A Ensor; A B Karpas; J G Morris; M B Sztein
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  MtaR, a regulator of methionine transport, is critical for survival of group B streptococcus in vivo.

Authors:  Daniel Shelver; Lakshmi Rajagopal; Theresa O Harris; Craig E Rubens
Journal:  J Bacteriol       Date:  2003-11       Impact factor: 3.490

4.  Membrane topology and DNA-binding ability of the Streptococcal CpsA protein.

Authors:  Brett R Hanson; Beth A Lowe; Melody N Neely
Journal:  J Bacteriol       Date:  2010-11-19       Impact factor: 3.490

5.  Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.

Authors:  Ravin Seepersaud; Sean B Hanniffy; Peter Mayne; Phil Sizer; Richard Le Page; Jerry M Wells
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

6.  Sialylation of group B streptococcal capsular polysaccharide is mediated by cpsK and is required for optimal capsule polymerization and expression.

Authors:  D O Chaffin; L M Mentele; C E Rubens
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

7.  Deletion of repeats in the alpha C protein enhances the pathogenicity of group B streptococci in immune mice.

Authors:  C Gravekamp; B Rosner; L C Madoff
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Identification and molecular characterization of a S. agalactiae strain lacking the capsular locus.

Authors:  R Creti; M Imperi; M Pataracchia; G Alfarone; S Recchia; L Baldassarri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-26       Impact factor: 3.267

9.  Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.

Authors:  Hsiao-Hui Yang; Lawrence C Madoff; Hilde-Kari Guttormsen; Yong-Dong Liu; Lawrence C Paoletti
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

10.  Molecular analysis of the Enterococcus faecalis serotype 2 polysaccharide determinant.

Authors:  Lynn E Hancock; Brett D Shepard; Michael S Gilmore
Journal:  J Bacteriol       Date:  2003-08       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.